Britain and America have agreed to a key commercial pact that will maintain no levies on British pharmaceutical products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the NHS. This move ensures that import taxes on these key products will be held at zero for a period of 36 months.
This agreement follows previous warnings to hike tariffs on patented pharmaceutical products, with potential rates discussed reaching one hundred percent.
"This deal between the Britain bolsters the international landscape for new treatments and brings much-needed balance to American-British medicine commerce," a statement said.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's largest exports to the US, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of September, the UK exported drugs valued at billions to the US. This value represented a significant portion of total UK exports in that timeframe.
"This agreement safeguards work, boosts funding and sets the stage for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key UK Commitments
The agreement entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Previously, refunds were more than 20%.
Industry Background
The deal follows a ongoing tension between the sector and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by assertions that US customers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
